HLB Genex has launched its supply of catalase, a specialized enzyme for semiconductor manufacturing, to the U.S. market, marking a significant step in its North American expansion strategy.
On Wednesday, HLB Genex announced the successful initiation of catalase shipments to new semiconductor foundries in the United States, capitalizing on its recently established global partnerships.
The company has already secured a dominant position in the catalase market for semiconductor processes in South Korea and Taiwan, showcasing its product excellence and reliable supply capabilities.
This new venture into the U.S. foundry market aligns with the global trend of expanding semiconductor production facilities, particularly in America. HLB Genex aims to leverage this opportunity to significantly boost its supply of high-value enzyme materials for semiconductor manufacturing.
Given that materials for semiconductor processes are typically used long-term once implemented, HLB Genex views this initial shipment as a crucial stepping stone for stable, long-term growth in the North American market.
As the company ramps up its international supply volume in response to growing global demand, it anticipates maintaining its robust performance and accelerating its growth trajectory.
In the first quarter of this year, HLB Genex reported consolidated sales of 11.7 billion KRW (approximately 7.76 million USD), a 9.13% increase from the same period last year. Operating profit rose by 25% to 1 billion KRW (about 663,000 USD), while the gross profit margin improved from 39% to 43%, indicating enhanced profitability.
Chief Executive Officer (CEO) Kim Do-yeon has demonstrated confidence in the company’s growth potential by purchasing shares in the open market. He acquired 10,380 shares in January, followed by 15,556 shares in April, and an additional 21,035 shares on May 18. These purchases have increased his total holdings from 38,646 to 59,681 shares.
Jin Yang-gon, chairman of the HLB Group, has also shown support by purchasing 68,401 shares of HLB Genex last month, bringing his total acquisitions this year to 128,020 shares.
An HLB Genex spokesperson stated that the initial shipment of catalase to new semiconductor foundries in the U.S. represents a pivotal moment for our high-value enzyme materials business as we expand globally. They’re committed to growing its sales of premium products, including semiconductor process enzymes, and enhancing shareholder value to ensure its corporate worth is accurately reflected in the market.
This strategic move into the U.S. semiconductor market positions HLB Genex to capitalize on the increasing demand for specialized materials in the rapidly evolving tech industry.
As the semiconductor industry continues to grow, particularly in the U.S., HLB Genex’s expansion could play a crucial role in supporting the global supply chain for these essential components.